These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

853 related articles for article (PubMed ID: 11769464)

  • 1. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors in congenital coagulation disorders.
    Key NS
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy reviews: clinical use of hemostatic agents.
    Lowe GD; Lawson DH
    Am J Hosp Pharm; 1978 Apr; 35(4):414-22. PubMed ID: 306196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with factor VIII: C inhibitors and acquired von Willebrand's disease in an adult at Ramathibodi Hospital.
    Angchaisuksiri P; Atichartakarn V; Pathepchotiwong K; Jootar S; Ungkanont A; Chuncharunee S
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():152-8. PubMed ID: 7886560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acquired hemophilia caused by autoantibodies against factor VIII coagulation activity. Clinical, biological study and therapeutic indications. Experience based on a study of 9 cases].
    Liozon E; Delaire L; Turlure P; Jaccard A; Loustaud-Ratti V; Réméniéras L; Julia A; Gaillard S; Bordessoule D; Vidal E
    Ann Med Interne (Paris); 1997; 148(7):477-90. PubMed ID: 9538386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
    Diniz MJ; Dias Francisco F; Tavares ML; Leal I
    Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of genetics in inhibitor formation.
    Gill JC
    Thromb Haemost; 1999 Aug; 82(2):500-4. PubMed ID: 10605742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
    Kershaw G; Jayakodi D; Dunkley S
    Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients.
    Scandella DH
    Semin Thromb Hemost; 2000; 26(2):137-42. PubMed ID: 10919405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic studies in asymptomatic hemophiliac patients.
    Frydecka I; Kowalewska B; Lesiecki A; Kuliczkowski K; Palakowska A; Polkowski A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):708-15. PubMed ID: 2435638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic factor VIII inhibitor autoantibody in a man presented after accident.
    Mansouritorghabeh H; Lak M; van Heerde WL
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):588-90. PubMed ID: 18550586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.